NASDAQ: NYXHNyxoah Sa Stock
$7.84+0.28 (+3.7%)
Updated Jul 14, 2025
NYXH Price
$7.84
Fair Value Price
N/A
Market Cap
$293.43M
52 Week Low
$5.55
52 Week High
$11.87
P/E
-3.52x
P/B
2.81x
P/S
55.07x
PEG
N/A
Dividend Yield
N/A
Revenue
$4.90M
Earnings
-$75.78M
Gross Margin
65.5%
Operating Margin
-1,342.26%
Profit Margin
-1,597.5%
Debt to Equity
0.46
Operating Cash Flow
-$60M
Beta
0.41
Next Earnings
Aug 6, 2025
Ex-Dividend
N/A
Next Dividend
N/A
NYXH Overview
Nyxoah S.A. is a health-techn company developing solutions for sleep disordered breathing conditions, including severe Obstructive Sleep Apnea, a common condition associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke. Nyxoah was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine NYXH's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical
Industry Rating
C
NYXH
Ranked#44 of 45
Ranked#44 of 45
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $5.61 | A | |
| $10.37 | B | |
| $93.45 | B |
Be the first to know about important NYXH news, forecast changes, insider trades & much more!
NYXH News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NYXH scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NYXH is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
NYXH is good value based on its book value relative to its share price (2.81x), compared to the US Medical Instruments & Supplies industry average (3.63x)
P/B vs Industry Valuation
NYXH is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more NYXH due diligence checks available for Premium users.
Valuation
NYXH price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.52x
Industry
39.73x
Market
31.22x
NYXH price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.81x
Industry
3.63x
NYXH is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NYXH's financial health
Profit margin
Revenue
$1.2M
Net Income
-$24.3M
Profit Margin
-2,103.8%
NYXH's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
NYXH's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$147.7M
Liabilities
$46.8M
Debt to equity
0.46
NYXH's short-term assets ($84.51M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NYXH's short-term assets ($84.51M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NYXH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$20.1M
Investing
$8.8M
Financing
-$793.5k
NYXH's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NYXH vs Medical Stocks
Nyxoah Sa Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.